First Trust Advisors LP lowered its position in shares of Medpace Holdings Inc (NASDAQ:MEDP) by 38.7% during the 1st quarter, HoldingsChannel reports. The firm owned 67,665 shares of the company’s stock after selling 42,633 shares during the period. First Trust Advisors LP’s holdings in Medpace were worth $3,990,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of MEDP. BlackRock Inc. lifted its holdings in shares of Medpace by 82.2% in the fourth quarter. BlackRock Inc. now owns 4,158,359 shares of the company’s stock worth $220,103,000 after buying an additional 1,876,296 shares in the last quarter. Wasatch Advisors Inc. lifted its holdings in shares of Medpace by 17.5% in the first quarter. Wasatch Advisors Inc. now owns 1,404,441 shares of the company’s stock worth $82,820,000 after buying an additional 209,449 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Medpace by 130.9% in the fourth quarter. Bank of New York Mellon Corp now owns 753,303 shares of the company’s stock worth $39,872,000 after buying an additional 427,062 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Medpace by 41.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 506,896 shares of the company’s stock worth $26,829,000 after buying an additional 147,472 shares in the last quarter. Finally, Prudential Financial Inc. lifted its holdings in shares of Medpace by 13.9% in the fourth quarter. Prudential Financial Inc. now owns 432,071 shares of the company’s stock worth $22,869,000 after buying an additional 52,761 shares in the last quarter. 76.70% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have recently commented on MEDP shares. Zacks Investment Research downgraded shares of Medpace from a “hold” rating to a “sell” rating in a report on Saturday, March 2nd. BidaskClub downgraded shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, March 9th. TheStreet downgraded shares of Medpace from a “b” rating to a “c” rating in a report on Friday, March 22nd. Wolfe Research started coverage on shares of Medpace in a report on Tuesday, April 2nd. They issued an “outperform” rating on the stock. Finally, ValuEngine downgraded shares of Medpace from a “buy” rating to a “hold” rating in a report on Tuesday, April 16th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Medpace presently has a consensus rating of “Buy” and a consensus price target of $59.25.

MEDP stock opened at $56.38 on Friday. Medpace Holdings Inc has a one year low of $41.84 and a one year high of $71.66. The company has a current ratio of 0.69, a quick ratio of 0.69 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $2.02 billion, a PE ratio of 21.77, a P/E/G ratio of 1.68 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, April 29th. The company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.60 by $0.04. The firm had revenue of $200.70 million for the quarter, compared to the consensus estimate of $190.16 million. Medpace had a net margin of 10.49% and a return on equity of 17.16%. The company’s quarterly revenue was up 23.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.60 earnings per share. On average, equities research analysts predict that Medpace Holdings Inc will post 2.64 EPS for the current year.

In related news, CFO Jesse J. Geiger sold 25,037 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $60.00, for a total transaction of $1,502,220.00. Following the sale, the chief financial officer now owns 25,037 shares of the company’s stock, valued at $1,502,220. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, General Counsel Stephen P. Ewald sold 7,946 shares of the company’s stock in a transaction on Friday, March 29th. The shares were sold at an average price of $57.95, for a total transaction of $460,470.70. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 44,983 shares of company stock worth $2,661,091. 24.20% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: “First Trust Advisors LP Has $3.99 Million Holdings in Medpace Holdings Inc (NASDAQ:MEDP)” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2019/06/14/first-trust-advisors-lp-has-3-99-million-holdings-in-medpace-holdings-inc-nasdaqmedp.html.

Medpace Company Profile

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Read More: What is the Quick Ratio?

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings Inc (NASDAQ:MEDP).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.